AVEO Oncology’s Fotivda Combo Fails to Meet Primary Endpoint in Phase III Renal Cell Carcinoma Study

1. AVEO Oncology's Phase III Trial Failure: AVEO Oncology's Phase III clinical trial, TiNivo-2, evaluating the combination of Fotivda (tivozanib) and nivolumab (Opdivo) in patients with advanced metastatic renal cell carcinoma (RCC) failed to meet its primary efficacy endpoint.
2. Fotivda Combo Falls Short: The oral drug Fotivda, in combination with nivolumab, did not achieve the primary endpoint in the Phase III study, indicating the regimen was not effective in treating RCC.
3. Trial Details: The TiNivo-2 study was designed to assess the efficacy and safety of the Fotivda and nivolumab combination in patients with advanced metastatic RCC.
4. Impact on Kidney Cancer Treatment: The failure of this trial may impact the development of new treatments for kidney cancer, specifically renal cell carcinoma, which is a significant unmet medical need.